BMRN · NASDAQ · STOCK
BioMarin Pharmaceutical (BMRN) Stock Analysis
$54.80
52W $49.26 – $70.98
51/100
$10.59B
144.2
0.22
Is BMRN Bullish or Bearish?
Mixed.
Innellis AI committee rates BioMarin Pharmaceutical (BMRN) Watch with a composite score of 51/100
, based on 6 analysts with 67% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +8.70 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -11.30 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Macro Analyst sees a compelling case. Portfolio Manager remains cautious — sector concentration is already high (hhi 2796.97). This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement — Technical
- Low leverage (debt-to-equity 0.10) -- balance sheet can absorb a shock — Risk
Bear Case
- P/E of 144.9 is expensive by classic value standards — Value
- ROE of only 1.2% -- cheap may mean cheap for a reason — Value
- EPS declining -89.2% YoY despite any revenue growth — Growth
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
- RSI at 13 is in oversold territory (could mean either capitulation or a bounce setup) — Technical
- MACD histogram negative -- bearish momentum — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
51/100
Agreement
67%
Analysts
6
Conviction
Moderate
Sector Rank
Top 90%
of 192 Healthcare peers
Value Analyst
neutral
44
/ 100 · High confidence
Fair value -- neither a bargain nor obviously overpriced
− P/E of 144.9 is expensive by classic value standards
Growth Analyst
bearish
40
/ 100 · High confidence
Growth story is weak, decelerating, or inconsistent
− EPS declining -89.2% YoY despite any revenue growth
Technical Analyst
neutral
46
/ 100 · High confidence
Mixed or range-bound price action
+ Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement
− RSI at 13 is in oversold territory (could mean either capitulation or a bounce setup)
Risk Analyst
neutral
58
/ 100 · Moderate confidence
Moderate risk -- no single red flag, but nothing that clearly de-risks the position either
+ Low leverage (debt-to-equity 0.10) -- balance sheet can absorb a shock
− Bollinger bandwidth of 24.6% signals elevated volatility
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
neutral
55
/ 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 51.3 to 51.3.
- New bearish signals: 2 appeared.
- Bearish pressure eased: 2 signal(s) disappeared.
Analyst-level changes:
- Risk Analyst: +1 bearish signal(s).
- Value Analyst: +1 bearish signal(s).
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
13.1
Oversold
MACD Histogram
-0.648
Bearish Momentum
Trend Direction
Sideways
Weekly: Sideways
Market Structure
Hh Hl
Support
$53.72
Resistance
$56.66
Bollinger %B
0.12
Inside Bands
Price vs Moving Averages
EMA 9
$56.96
Below
EMA 21
$59.61
Below
EMA 50
$61.31
Below
EMA 200
$59.57
Below
Fundamental Analysis
Valuation
66
Growth
28
Profitability
46
Financial Health
96
Cash Flow
70
Valuation
P/E Ratio
144.2×
P/B Ratio
1.67×
PEG Ratio
-1.62
Dividend Yield
0.00%
52W High
$70.98
52W Low
$49.26
Quality & Growth
ROE
573.2%
ROA
459.4%
Gross Margin
7554.8%
Operating Margin
802.1%
Revenue Growth YoY
—
Debt / Equity
0.66
AI Fundamental Assessment
P/E ratio of 144.2 (rich relative to a 15-40x range); Price-to-book of 1.7x; PEG ratio of -1.6 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 5.7%; Return on assets of 4.6%; Net margin of 2.1%; Gross margin of 75.5%; Current ratio of 2.39 (healthy short-term liquidity); Debt-to-equity of 0.66; Free cash flow per share is positive (3.80); Most recent quarter beat estimates by 4.0%; EPS growth decelerating (+325.0% -> +35.2% QoQ); Average YoY EPS growth of -40.6%; Analyst estimates rising over recent quarters
Get the Full BMRN Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →